Omeros (NASDAQ:OMER) Given “Overweight” Rating at Cantor Fitzgerald

Omeros (NASDAQ:OMER)‘s stock had its “overweight” rating reiterated by analysts at Cantor Fitzgerald in a note issued to investors on Wednesday, Marketbeat reports. They currently have a $22.00 price target on the biopharmaceutical company’s stock. Cantor Fitzgerald’s price objective points to a potential upside of 16.75% from the stock’s current price.

A number of other analysts have also issued reports on the company. Weiss Ratings raised Omeros from a “hold (c-)” rating to a “hold (c)” rating in a report on Thursday, October 8th. Zacks Research cut shares of Omeros from a “strong-buy” rating to a “hold” rating in a research note on Monday, July 13th. Wall Street Zen raised Omeros from a “hold” rating to a “buy” rating in a research note on Saturday, August 15th. Finally, HC Wainwright restated a “buy” rating on shares of Omeros in a research report on Monday, July 27th. One equities research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $34.00.

Omeros Trading Down 0.2%

Omeros stock traded down $0.04 during trading hours on Wednesday, reaching $18.84. 331,674 shares of the company were exchanged, compared to its average volume of 1,647,739. Omeros has a 12 month low of $6.24 and a 12 month high of $21.24. The stock has a 50-day moving average of $18.12 and a 200 day moving average of $13.72. The firm has a market cap of $1.36 billion, a price-to-earnings ratio of 14.75 and a beta of 2.57.

Omeros (NASDAQ:OMER) last issued its quarterly earnings data on Wednesday, August 12th. The biopharmaceutical company reported $0.02 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.27) by $0.29. The firm had revenue of $28.53 million during the quarter, compared to analyst estimates of $12.69 million. As a group, research analysts forecast that Omeros will post -0.37 EPS for the current year.

Insider Transactions at Omeros

In related news, Director Arnold Hanish sold 10,000 shares of Omeros stock in a transaction dated Thursday, August 27th. The stock was sold at an average price of $18.95, for a total value of $189,500.00. Following the completion of the sale, the director directly owned 5,000 shares in the company, valued at $94,750. This trade represents a 66.67% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CAO David Borges sold 10,000 shares of the company’s stock in a transaction dated Friday, August 21st. The shares were sold at an average price of $18.95, for a total transaction of $189,500.00. Following the transaction, the chief accounting officer owned 5,906 shares in the company, valued at approximately $111,918.70. The trade was a 62.87% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 105,906 shares of company stock worth $1,989,705 in the last ninety days. 10.50% of the stock is currently owned by insiders.

Institutional Trading of Omeros

Institutional investors and hedge funds have recently made changes to their positions in the business. GK Wealth Management LLC bought a new stake in shares of Omeros in the 3rd quarter valued at about $65,000. State Street Corp grew its holdings in Omeros by 20.9% during the second quarter. State Street Corp now owns 2,319,906 shares of the biopharmaceutical company’s stock valued at $22,062,000 after purchasing an additional 400,331 shares during the period. Engineers Gate Manager LP bought a new stake in Omeros in the second quarter valued at approximately $138,000. Squarepoint Ops LLC bought a new stake in shares of Omeros in the 2nd quarter valued at $523,000. Finally, Arizona State Retirement System acquired a new stake in Omeros during the 2nd quarter worth $179,000. Institutional investors own 48.79% of the company’s stock.

About Omeros

Omeros Corporation (NASDAQ: OMER) is a biopharmaceutical company focused on discovering, developing and commercializing therapies for disorders involving the complement, immune and coagulation systems. The company has also developed a pipeline of investigational therapies aimed at treating serious diseases involving complement activation and immune-system dysfunction. The company is headquartered in Seattle, Washington, and was founded in 1994.

Its leading investigational programs have included narsoplimab, which targets the lectin pathway of the complement system, and OMS906, an antibody designed to inhibit MASP-3 and regulate the alternative pathway.